Author of

• 12441

  +

  P3.06 - Poster Session 3 - Prognostic and Predictive Biomarkers (ID 178)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12476

    +

    P3.06-036 - Prospective correlative study of FDG-PET SUV and proteomic profile (VeriStrat) of Non Small Cell Lung Cancer (NSCLC) patients treated with erlotinib (ID 2693)

    09:30 - 09:30  |  Author(s): M. Scarlattei
    • Abstract

    Background
    VeriStrat (VS) is a multivariate protein serum test that classifies Non Small Cell Lung Cancer (NSCLC) patients in 2 categories VS Good or VS Poor according to the overall survival (OS) of patients treated with EGFR-TKIs. Recently, the prospective Phase III PROSE study showed that the VS algorithm is predictive of differential OS benefit for erlotinib (E) vs second line standard chemotherapy (CT): VS Poor classified patients had worse OS on E compared to CT, while there was no significant difference between treatments outcome in the VSG group. Aim of the current study was to evaluate if baseline Standardized Uptake Value (SUV) of FDG-PET may help to optimize treatment choice between E or CT IN VS Good classified pts.

    Methods
    Plasma samples were collected before the beginning of E from metastatic NSCLC patients. Acquired spectra were classified according to the VS algorithm. The FDG-PET was performed tha day before the beginning of E. Survival curves were estimated using the Kaplan-Meier method.

    Results
    Thirty eight NSCLC patients on E therapy with the following characteristics were analyzed: median age 62 years old, 63% were males, 53% had adenocarcinoma histology, response rate was 26%, median OS 10 mos and TTP 3.4 mos. Twenty-six (68%) were classified as VS Good, 12 (32%) as Poor. TTP and OS for VS Good and Poor were 4.1 vs 2.1 mos (HR 0.86, log-rank p=0.6) and 11.1 vs 4.1 mos (HR 0.45,log-rank p=0.02), respectively. All VS Poor classified patients had SUV ≥ 7 and had the worst TTP and OS; VS Good classified patients with baseline SUV level ≥ 7 had worse OS (10 mos) and worse TTP (2.1 mos) compared to those who were VS Good and had SUV<7 (OS 16 mos) (TTP 13.8 mos).

    Conclusion
    The study confirmed that VS Poor classified patients had significantly shorter OS than those classified as VS Good. Patients with VS Good profile and with baseline FDG-PET SUVs levels <7 may benefit more from EGFR-TKIs than VS Good patients with higher FDG-PET SUV, suggesting that FDG-PET analysis may be a clinically useful tool for EGFR-TKIs therapy selection.